Surgery Partners, Inc. Website

Surgery Partners, Inc.

NasdaqGS-SGRY

Company Overview

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

  • Name

    Surgery Partners, Inc.

  • CEO

    J. Eric Evans

  • Website

    www.surgerypartners.com

  • Sector

    Health Care Providers and Services

  • Year Founded

    2004

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Surgery Partners Inc. Navigates Mixed Market Sentiments Amid Analyst Support

  • Surgery Partners Inc. received a "Moderate Buy" consensus rating from ten brokerage firms, with seven analysts recommending a buy despite mixed price target sentiments.
  • A significant downgrade from JPMorgan raised concerns over reduced revenue guidance and led to substantial stock declines.
  • Ongoing investigations related to financial disclosures have compounded challenges for the company, yet its strategic focus on expanding surgical services continues to attract investor interest.

Over the past month, Surgery Partners Inc. (SGRY) experienced an overall increase of 5.0% in its stock price, significantly outperforming the S&P 500's return of 0.7%. This performance reflects a complex interplay between bullish and bearish sentiments affecting the company during this period.

The bullish sentiment was primarily driven by positive analyst ratings and reports of revenue growth. On December 1, SGRY achieved a consensus rating of "Moderate Buy," with seven out of ten analysts recommending a buy despite mixed views on price targets from Mizuho and JPMorgan. The company reported an impressive year-over-year revenue increase of 6.6%, although it did miss earnings expectations for its latest quarter.

Conversely, several bearish events negatively impacted SGRY's performance throughout the month. A downgrade from JPMorgan on November 24 lowered their price target to $20 due to concerns over reduced full-year revenue guidance and adjusted EBITDA forecasts stemming from delays in capital deployment and lost earnings from divestitures of ambulatory surgical centers. Following these announcements, SGRY’s stock saw significant declines; notably closing at $16.04 after dropping over $5 per share on November 10 due to disappointing financial results that prompted an investigation into potential claims against the firm.

Further compounding these challenges were ongoing investigations initiated by Bronstein, Gewirtz & Grossman concerning Surgery Partners' recent financial disclosures that highlighted issues with commercial payer mix and volume projections for Q4. Despite these setbacks leading to negative market reactions—evident through multiple days of losses—the company's strategic focus on expanding surgical services continued to attract some investor interest.

Overall, while there were considerable headwinds impacting Surgery Partners’ stock performance through downgrades and investigations during this one-month period, positive analyst support helped mitigate some losses as evidenced by its outperformance relative not only to broader market indices but also within its sector context where it outperformed Health Care (XLV) sector returns by 3.1%.

NasdaqGS:SGRY